1 N6-Ethenoadenosine free base manufacturers
|
| | 1 N6-Ethenoadenosine free base Basic information |
| Product Name: | 1 N6-Ethenoadenosine free base | | Synonyms: | 1,N6-Ethenoadenosine;ETHENOADENOSINE, MORPURE HPLC PURIFIED, DELIVERED >= 98% PURE WITH HPLC UV CHROMATOGRAM;1,N(sup 6)-ethenoadenosine;3-(β-D-Ribofuranosyl)-3,5a-dihydro-1,3,4,5a,8-pentaaza-as-indacene;3-(β-D-Ribofuranosyl)-3H-imidazo[2,1-i]purine;3-β-D-Ribofuranosyl-3H-imidazo[2,1-i]purine;N6-Ethenoadenosine;(2R,3S,4R,5R)-2-(Hydroxymethyl)-5-(3H-imidazo[2,1-i]purin-3-yl)tetrahydrofuran-3,4-diol | | CAS: | 39007-51-7 | | MF: | C12H13N5O4 | | MW: | 291.26 | | EINECS: | | | Product Categories: | | | Mol File: | 39007-51-7.mol |  |
| | 1 N6-Ethenoadenosine free base Chemical Properties |
| density | 1.99±0.1 g/cm3(Predicted) | | storage temp. | −20°C | | pka | 13.19±0.70(Predicted) | | form | Solid | | color | White to off-white |
| | 1 N6-Ethenoadenosine free base Usage And Synthesis |
| Uses | 1,N6-Ethenoadenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc[1]. | | References | [1] Robak T, Robak P. Purine nucleoside analogs in the treatment of rarer chronic lymphoid leukemias. Curr Pharm Des. 2012;18(23):3373-88. DOI:10.2174/138161212801227005 |
| | 1 N6-Ethenoadenosine free base Preparation Products And Raw materials |
|